VIDEO: Long-term ibrutinib therapy possible ‘great option’ for high-risk CLL
In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed updated data from the ALLIANCE study for chronic lymphocytic leukemia presented at ASH Annual Meeting and Exposition.
The long-term results showed that ibrutinib-based regimens remained superior to bendamustine plus rituximab in terms of PFS, and there was no difference in the rates of PFS in the presence or absence of rituximab, Davids said.
He also said “one of the most striking take-aways” from this presentation was that the study included patients with deletion 17p, the highest risk form of CLL. Though it’s common for these patients to have shorter PFS on other regimens than those without deletion 17p, patients in this study had the same PFS in both of the ibrutinib arms regardless of their status, Davids said.
“It really does suggest that continuous ibrutinib therapy is a great option for these patients with high-risk CLL and they can enjoy these durable responses,” Davids told Healio.
Collapse
Woyach JA, et al. Abstract 639. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Read more about